An intrahepatic cholangiocarcinoma that produces abundant mucin.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for mucinous intrahepatic cholangiocarcinoma is limited due to its rarity, which affects fewer than 5,000 people in the United States. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. As research continues, more information may become available to better understand this condition.
To navigate your care, consider seeking a specialist in hepatobiliary oncology or a medical oncologist with experience in cholangiocarcinoma. You may also benefit from participating in clinical trials, which can provide access to cutting-edge treatments. For more information on clinical trials, visit ClinicalTrials.gov. While there are currently no specific patient organizations identified for this condition, the National Organization for Rare Disorders (NORD) offers resources that may be helpful: https://rarediseases.org.
There are currently two FDA-approved treatments for mucinous intrahepatic cholangiocarcinoma: ivosidenib and pemigatinib. Additionally, several orphan drugs are in development, including various targeted therapies and immunotherapies. For ongoing research, you can explore active clinical trials at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=mucinous%20intrahepatic%20cholangiocarcinoma. This research landscape offers hope for future treatment options.
Actionable guidance for navigating care for mucinous intrahepatic cholangiocarcinoma
To navigate your care, consider seeking a specialist in hepatobiliary oncology or a medical oncologist with experience in cholangiocarcinoma. You may also benefit from participating in clinical trials, which can provide access to cutting-edge treatments. For more information on clinical trials, visit ClinicalTrials.gov. While there are currently no specific patient organizations identified for this condition, the National Organization for Rare Disorders (NORD) offers resources that may be helpful: https://rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mucinous intrahepatic cholangiocarcinoma is limited due to its rarity, which affects fewer than 5,000 people in the United States. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. As research continues, more information may become available to better understand this condition.
To navigate your care, consider seeking a specialist in hepatobiliary oncology or a medical oncologist with experience in cholangiocarcinoma. You may also benefit from participating in clinical trials, which can provide access to cutting-edge treatments. For more information on clinical trials, visit ClinicalTrials.gov. While there are currently no specific patient organizations identified for this condition, the National Organization for Rare Disorders (NORD) offers resources that may be helpful: https://rarediseases.org.
There are currently two FDA-approved treatments for mucinous intrahepatic cholangiocarcinoma: ivosidenib and pemigatinib. Additionally, several orphan drugs are in development, including various targeted therapies and immunotherapies. For ongoing research, you can explore active clinical trials at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=mucinous%20intrahepatic%20cholangiocarcinoma. This research landscape offers hope for future treatment options.
Actionable guidance for navigating care for mucinous intrahepatic cholangiocarcinoma
To navigate your care, consider seeking a specialist in hepatobiliary oncology or a medical oncologist with experience in cholangiocarcinoma. You may also benefit from participating in clinical trials, which can provide access to cutting-edge treatments. For more information on clinical trials, visit ClinicalTrials.gov. While there are currently no specific patient organizations identified for this condition, the National Organization for Rare Disorders (NORD) offers resources that may be helpful: https://rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mucinous intrahepatic cholangiocarcinoma is limited due to its rarity, which affects fewer than 5,000 people in the United States. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. As research continues, more information may become available to better understand this condition.
To navigate your care, consider seeking a specialist in hepatobiliary oncology or a medical oncologist with experience in cholangiocarcinoma. You may also benefit from participating in clinical trials, which can provide access to cutting-edge treatments. For more information on clinical trials, visit ClinicalTrials.gov. While there are currently no specific patient organizations identified for this condition, the National Organization for Rare Disorders (NORD) offers resources that may be helpful: https://rarediseases.org.
There are currently two FDA-approved treatments for mucinous intrahepatic cholangiocarcinoma: ivosidenib and pemigatinib. Additionally, several orphan drugs are in development, including various targeted therapies and immunotherapies. For ongoing research, you can explore active clinical trials at ClinicalTrials.gov using the following link: https://clinicaltrials.gov/search?cond=mucinous%20intrahepatic%20cholangiocarcinoma. This research landscape offers hope for future treatment options.
Actionable guidance for navigating care for mucinous intrahepatic cholangiocarcinoma
To navigate your care, consider seeking a specialist in hepatobiliary oncology or a medical oncologist with experience in cholangiocarcinoma. You may also benefit from participating in clinical trials, which can provide access to cutting-edge treatments. For more information on clinical trials, visit ClinicalTrials.gov. While there are currently no specific patient organizations identified for this condition, the National Organization for Rare Disorders (NORD) offers resources that may be helpful: https://rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.